The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; MSD; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Yakuhin (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; MSD; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Toshimi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Hisamitsu Pharmaceutical; Lilly; MSD; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
 
Michiko Tsuneizumi
No Relationships to Disclose
 
Akiyo Yoshimura
Honoraria - ACTmed; AstraZeneca; Chugai Pharma; Lilly; Pfizer
 
Masato Takahashi
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD; Pfizer
Research Funding - Eisai (Inst); Nippon Kayaku (Inst)
 
Junji Tsurutani
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Nihonkayaku; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Daiichi Sankyo; Lilly; Seagen
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Kirin (Inst); Lilly (Inst); MSD Oncology (Inst); Nihonkayaku (Inst); Sant Joan de Déu Research Foundation (FSJD) (Inst); West Japan Oncology Group (Inst); West Japan Oncology Group (Inst)
 
Tsuguo Iwatani
Speakers' Bureau - Eisai
 
Masahiro Kitada
No Relationships to Disclose
 
Hiroshi Tada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Kyowa Kirin International; Lilly Japan; MSD; Novartis; Pfizer; Takeda
 
Natsuko Mori
No Relationships to Disclose
 
Toru Higuchi
No Relationships to Disclose
 
Tsutomu Iwasa
No Relationships to Disclose
 
Kazuhiro Araki
No Relationships to Disclose
 
Kazuko Sakai
Honoraria - Nippon Kayaku; Qiagen, Inc.; Takeda; YODOSHA
 
Hiroki Hasegawa
Employment - Eisai; Syneos Health (I)
Stock and Other Ownership Interests - Abbvie; Eisai; Takeda
 
Yohei Uchida
Employment - Eisai
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group; Japan Society of Clinical Oncology (JSCO); Japanese Breast Cancer Society
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Kyowa-Kirin; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono-Pharma (Inst); Pfizer (Inst); Sanofi (Inst)